An Improved Method for the Production of Ac‐225/Bi‐213 from Th‐229 for Targeted Alpha Therapy
An Improved Method for the Production of Ac‐225/Bi‐213 from Th‐229 for Targeted Alpha Therapy
复制标题
一种从 Th-229 生产 Ac-225/Bi-213 用于靶向 Alpha 治疗的改进方法
DOI：
--
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
A. Morgenstern
中科院分区：
文献类型：
--
作者：
B. Zielinska;C. Apostolidis;F. Bruchertseifer;A. Morgenstern
摘要这项工作描述了一种改进的Re/Ac分离方法，作为从Th-229源生产Ac-225的过程的一部分，用于癌症的靶向阿尔法治疗。这种分离方法是基于使用一种新开发的含有二乙醇酰胺(DGA)类分子的萃取层析树脂。研究了Ac(III)在N，N，N‘N’四辛基二乙醇酰胺(TODGA)和N，N‘N’四乙基己基二乙醇酰胺(TEHDGA)(Eichrom Inc.)萃淋树脂上的质量分配比。在不同的硝酸和盐酸浓度下，通过间歇实验优化了Ac(III)和Ra(II)的分离条件。因此，开发了一种基于TEHDGA树脂的可靠和快速的方法，生产出了无载体、临床级别的AC-225，总收率超过98%。
Abstract This work describes an improved method for radium/actinium separation as part of a process for the production of Ac‐225 from a Th‐229 source for targeted alpha therapy of cancer. The separation method is based on the use of a newly developed extraction chromatographic resin containing the diglycolamide (DGA) class of molecules. The weight distribution ratios of Ac(III) on the extraction chromatographic resins N,N,N′N′ tetraoctyldiglycolamide (TODGA) and N,N,N′N′ tetrakis‐2‐ethylhexyldiglycolamide (TEHDGA) (both Eichrom Inc.) were determined at varying nitric and hydrochloric acid concentrations by batch experiments to optimize conditions for the separation of Ac(III) from Ra(II). Consequently, a robust and rapid procedure based on the use of TEHDGA resin was developed yielding a carrier‐free, clinical‐grade Ac‐225 with an overall yield exceeding 98%.